|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61P 19/08 | (2006.01) |
| A61K 47/60 | (2017.01) | ||
| A61K 47/68 | (2017.01) |
| (11) | Number of the document | 3400065 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17700906.5 |
| Date of filing the European patent application | 2017-01-05 | |
| (97) | Date of publication of the European application | 2018-11-14 |
| (45) | Date of publication and mention of the grant of the patent | 2025-12-17 |
| (46) | Date of publication of the claims translation | 2026-03-10 |
| (86) | Number | PCT/EP2017/050224 |
| Date | 2017-01-05 |
| (87) | Number | WO 2017/118707 |
| Date | 2017-07-13 |
| (30) | Number | Date | Country code |
| 16150635 | 2016-01-08 | EP | |
| 16179293 | 2016-07-13 | EP | |
| 16191482 | 2016-09-29 | EP |
| (72) |
SPROGØE, Kennett , DK
RAU, Harald , DE
CLEEMANN, Felix , DE
HERSEL, Ulrich , DE
RASMUSSEN, Caroline Elisabeth , DK
|
| (73) |
Ascendis Pharma Growth Disorders A/S ,
Tuborg Boulevard 12, 2900 Hellerup,
DK
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Kontroliuojamo atpalaidavimo CNP agonistai, pasižymintys mažesniu šalutiniu poveikiu |
| CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS |
| Payment date | Validity (years) | Amount | |
| 2026-01-23 | 10 | 231.00 EUR |
| 2027-01-05 |